ETF Holdings Breakdown of FDMT

FDMT institutional holdings

The adjusted close for FDMT on 2025-11-11 was 10.80

The following institutional investment holdings of FDMT have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	32,151	USD 347,231 5.8%	10.80
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	32,151	USD 347,231 5.8%	10.80
Total =		64,302	USD 694,462

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with FDMT

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eleven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have assigned a buy recommendation to the company. […] - 2025-08-19 04:19:16

4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (D-) Rating at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report released on Thursday,Weiss Ratings reports. Other equities research analysts have also recently issued research reports about the company. Roth Capital dropped their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a […] - 2025-08-15 04:50:58

Roth Capital Issues Pessimistic Forecast for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) had its price target cut by Roth Capital from $44.00 to $38.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Roth Capital’s target price points to a potential upside of 469.72% from the company’s current price. […] - 2025-08-14 03:14:54

Bank of New York Mellon Corp Trims Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Bank of New York Mellon Corp reduced its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 7.6% during the first quarter, Holdings Channel reports. The firm owned 134,849 shares of the company’s stock after selling 11,092 shares during the quarter. Bank of New York Mellon Corp’s holdings in 4D Molecular […] - 2025-08-04 05:58:54

Pre-Market Most Active for Aug 1, 2025 : TSLL, NAMM, SQQQ, FDMT, NVDA, FIG, TLT, NVO, BAX, BBAI, NIO, JOBY

The NASDAQ 100 Pre-Market Indicator is down -196.46 to 23,021.66. The total Pre-Market volume is currently 178,283,434 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is -0.09 at $10.59, with 15,969,442 - 2025-08-01 09:29:53

4D Molecular Therapeutics (NASDAQ:FDMT) Earns “Sell (D-)” Rating from Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “sell (d-)” rating reissued by investment analysts at Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports. Several other research analysts have also recently issued reports on FDMT. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares […] - 2025-07-31 02:28:50

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of “Moderate Buy” from Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have issued a buy recommendation on the company. […] - 2025-07-25 05:48:57

4D Molecular Therapeutics (NASDAQ:FDMT) Given Buy Rating at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report released on Thursday,Benzinga reports. They currently have a $25.00 price objective on the stock. A number of other research firms have also recently commented on FDMT. Barclays reduced their price target on shares of 4D Molecular […] - 2025-07-04 04:59:45

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 2,925 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 7.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,324 shares of the company’s stock after […] - 2025-06-13 04:32:51

ProShare Advisors LLC Has $91,000 Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

ProShare Advisors LLC boosted its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 30.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,369 shares of the company’s stock after acquiring an additional 3,783 shares […] - 2025-06-04 04:58:50

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Purchased by Two Sigma Advisers LP

Two Sigma Advisers LP raised its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 452.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 126,400 shares of the company’s stock after purchasing an additional 103,500 shares during the […] - 2025-06-03 06:04:53

4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “sell (e+)” rating reaffirmed by equities researchers at Weiss Ratings in a report released on Saturday,Weiss Ratings reports. A number of other equities research analysts have also recently commented on FDMT. The Goldman Sachs Group reduced their target price on shares of 4D Molecular […] - 2025-05-27 05:26:57

Millennium Management LLC Has $7.91 Million Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Millennium Management LLC lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 1,607.1% during the 4th quarter, HoldingsChannel reports. The firm owned 1,420,723 shares of the company’s stock after acquiring an additional 1,337,497 shares during the period. Millennium Management LLC’s holdings in 4D Molecular Therapeutics were worth $7,913,000 at […] - 2025-05-27 04:49:00

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Holdings Lifted by Hsbc Holdings PLC

Hsbc Holdings PLC lifted its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 88.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 34,413 shares of the company’s stock after buying an additional 16,142 shares during the […] - 2025-05-12 05:30:48

The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00

4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price objective trimmed by The Goldman Sachs Group from $51.00 to $44.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other analysts also recently weighed in on the stock. HC Wainwright reissued a […] - 2025-05-12 02:58:50

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $26.71 Consensus Target Price from Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have assigned a buy […] - 2025-05-11 05:40:59

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by MetLife Investment Management LLC

MetLife Investment Management LLC increased its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 21.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,395 shares of the company’s stock after acquiring an additional 6,312 […] - 2025-05-09 05:20:52

Marshall Wace LLP Decreases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Marshall Wace LLP lessened its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 68.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 52,744 shares of the company’s stock after selling 112,449 shares during the quarter. Marshall Wace […] - 2025-05-05 05:02:59

Norges Bank Purchases Shares of 500,823 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Norges Bank acquired a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 500,823 shares of the company’s stock, valued at approximately $2,790,000. Norges Bank owned approximately 1.08% of 4D Molecular Therapeutics at the […] - 2025-04-11 05:14:55

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been given an average rating of “Moderate Buy” by the nine brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy […] - 2025-04-11 04:32:50

Mitsubishi UFJ Asset Management Co. Ltd. Purchases 17,576 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 168.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 28,041 shares of the company’s stock after acquiring an additional 17,576 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in 4D […] - 2025-04-04 05:12:57

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC reduced its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 11.8% during the 4th quarter, HoldingsChannel reports. The fund owned 21,834 shares of the company’s stock after selling 2,927 shares during the period. Intech Investment Management LLC’s holdings in 4D Molecular Therapeutics were worth $122,000 at […] - 2025-03-28 05:56:53

4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report sent to investors on Saturday,Weiss Ratings reports. FDMT has been the subject of several other research reports. Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $39.00 to […] - 2025-03-24 04:50:44

AlphaQuest LLC Purchases 14,441 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

AlphaQuest LLC lifted its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 3,665.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 14,835 shares of the company’s stock after purchasing an additional 14,441 shares during the quarter. AlphaQuest LLC’s holdings in 4D Molecular Therapeutics were worth $83,000 at the […] - 2025-03-20 06:16:50

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Sees Significant Decrease in Short Interest

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) was the target of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 5,240,000 shares, a decline of 15.1% from the February 13th total of 6,170,000 shares. Approximately 12.2% of the shares of the company […] - 2025-03-20 05:42:55

Daiwa Securities Group Inc. Has $55,000 Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Daiwa Securities Group Inc. grew its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 5,291.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,921 shares of the company’s stock after purchasing an additional 9,737 shares during the […] - 2025-03-18 05:42:56

Proficio Capital Partners LLC Buys 10,000 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Proficio Capital Partners LLC boosted its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 100.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 20,000 shares of the company’s stock after buying an additional 10,000 shares during the period. Proficio Capital Partners […] - 2025-03-13 05:09:05

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $40.00 Price Target at Bank of America

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) had its price target dropped by stock analysts at Bank of America from $42.00 to $40.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. A number of other brokerages also recently commented on FDMT. Leerink Partners decreased […] - 2025-03-12 04:00:49

Financial Contrast: 4D Molecular Therapeutics (NASDAQ:FDMT) and Moderna (NASDAQ:MRNA)

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) and Moderna (NASDAQ:MRNA – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership. Valuation & Earnings This table compares 4D Molecular […] - 2025-03-06 06:37:55

Chardan Capital Issues Pessimistic Forecast for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price

4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its target price reduced by Chardan Capital from $30.00 to $28.00 in a research report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock. Several other equities analysts have also issued reports on the stock. Royal Bank of Canada cut their price target […] - 2025-03-05 06:26:55

Back to Listing

Disclaimer